Xiong S - Search Results

1

The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes.

Mori R, Dorff TB, Xiong S, Tarabolous CJ, Ye W, Groshen S, Danenberg KD, Danenberg PV, Pinski JK. Mori R, et al. Among authors: xiong s. Prostate. 2010 Nov 1;70(15):1692-700. doi: 10.1002/pros.21204. Prostate. 2010. PMID: 20564320

2

A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer.

Dorff TB, Groshen S, Tsao-Wei DD, Xiong S, Gross ME, Vogelzang N, Quinn DI, Pinski JK. Dorff TB, et al. Among authors: xiong s. Prostate Cancer Prostatic Dis. 2014 Dec;17(4):359-65. doi: 10.1038/pcan.2014.37. Epub 2014 Sep 23. Prostate Cancer Prostatic Dis. 2014. PMID: 25245366 Free PMC article. Clinical Trial.

3

Effect of luteinizing hormone on the steroidogenic pathway in prostate cancer.

Pinski J, Xiong S, Wang Q, Stanczyk F, Hawes D, Liu SV. Pinski J, et al. Among authors: xiong s. Prostate. 2011 Jun 1;71(8):892-8. doi: 10.1002/pros.21305. Epub 2010 Nov 17. Prostate. 2011. PMID: 21456071

4

Ethnic differences in neuroendocrine expression in prostate cancer tissue.

Dorff TB, Liu SV, Xiong S, Cai J, Hawes D, Pinski J. Dorff TB, et al. Among authors: xiong s. Anticancer Res. 2011 Nov;31(11):3897-901. Anticancer Res. 2011. PMID: 22110216

5

Effects of luteinizing hormone receptor signaling in prostate cancer cells.

Xiong S, Wang Q, Liu SV, Montgomery RB, Stanczyk FZ, Vallone JG, Merin NM, Pinski J. Xiong S, et al. Prostate. 2015 Feb;75(2):141-50. doi: 10.1002/pros.22899. Epub 2014 Nov 12. Prostate. 2015. PMID: 25393079

6

Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells.

Mori R, Xiong S, Wang Q, Tarabolous C, Shimada H, Panteris E, Danenberg KD, Danenberg PV, Pinski JK. Mori R, et al. Among authors: xiong s. Prostate. 2009 Jan 1;69(1):12-23. doi: 10.1002/pros.20851. Prostate. 2009. PMID: 18814146

7

Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists.

Liu SV, Schally AV, Hawes D, Xiong S, Fazli L, Gleave M, Cai J, Groshen S, Brands F, Engel J, Pinski J. Liu SV, et al. Among authors: xiong s. Clin Cancer Res. 2010 Sep 15;16(18):4675-80. doi: 10.1158/1078-0432.CCR-10-1113. Epub 2010 Jul 29. Clin Cancer Res. 2010. PMID: 20670943

8

Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer.

Dorff TB, Tsao-Wei DD, Groshen S, Boswell W, Goldkorn A, Xiong S, Quinn DI, Pinski JK. Dorff TB, et al. Among authors: xiong s. Clin Genitourin Cancer. 2013 Dec;11(4):416-22. doi: 10.1016/j.clgc.2013.07.011. Epub 2013 Oct 4. Clin Genitourin Cancer. 2013. PMID: 24099865 Clinical Trial.

9

Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer.

Liu SV, Tsao-Wei DD, Xiong S, Groshen S, Dorff TB, Quinn DI, Tai YC, Engel J, Hawes D, Schally AV, Pinski JK. Liu SV, et al. Among authors: xiong s. Clin Cancer Res. 2014 Dec 15;20(24):6277-83. doi: 10.1158/1078-0432.CCR-14-0489. Epub 2014 Oct 2. Clin Cancer Res. 2014. PMID: 25278449 Clinical Trial.

10

A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer.

Yu SS, Athreya K, Liu SV, Schally AV, Tsao-Wei D, Groshen S, Quinn DI, Dorff TB, Xiong S, Engel J, Pinski J. Yu SS, et al. Among authors: xiong s. Clin Genitourin Cancer. 2017 Dec;15(6):742-749. doi: 10.1016/j.clgc.2017.06.002. Epub 2017 Jun 8. Clin Genitourin Cancer. 2017. PMID: 28668277 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,316 results

Search Page

Filters